Vir Biotechnology Inc (VIR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.64B
Last updated: Nov 17, 2026 at 4:28 PM ET
Vir Biotechnology Inc (VIR) Statistics
Vir Biotechnology (VIR) has a market cap of $1.64B and an enterprise value of $1.42B. Revenue grew 1697.56% over the last 12 months from the 12 months before. Its share count is up 21.84% from a year earlier.
Total Valuation
Enterprise value is 13.34% below the market cap, as cash exceeds debt.
| Market Cap | $1.64B |
|---|---|
| Enterprise Value | $1.42B |
| Latest price (Nov 17, 2026) | $9.25 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.2x and 1.7x. Its year-end P/S ranged from 2.1x to 62.6x from 2019 to 2025.
| P/S Ratio | 5.2x |
|---|---|
| Forward P/S | 5.0x |
| P/B Ratio | 1.7x |
| P/TBV Ratio | 1.8x |
Price Statistics
The stock is up 64.30% over 52 weeks and trades 16.44% below its 50-day average.
| Beta (1Y) | 1.81 |
|---|---|
| 52-Week Change | +64.30% |
| 1-Month Change | -9.40% |
| 3-Month Change | -5.32% |
| 6-Month Change | +8.44% |
| 5-Year Change | -70.05% |
| Total Return (1Y) | +64.30% |
| Total Return (3Y CAGR) | -1.54% |
| Total Return (5Y CAGR) | -21.84% |
| Return vs SPY (1Y) | +56.62% |
| Max Drawdown (1Y) | -32.21% |
| Max Drawdown (3Y) | -66.19% |
| Sharpe Ratio (1Y) | 0.78 |
| Correlation with SPY (1Y) | 0.37 |
| 50-Day Average | $11.07 |
| 200-Day Average | $9.78 |
| 52-Week Range | $5.32 to $14.38 |
| RSI (14 Days) | 37.1 |
| Average Volume (20 Days) | 3.04M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.30x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.30x |
|---|---|
| Quick Ratio | 6.30x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -20.62% over the last 12 months, against a 5-year average of -15.91%.
| Return on Equity (ROE) | -20.62% |
|---|---|
| Return on Assets (ROA) | -16.62% |
| ROE (5Y Average) | -15.91% |
| ROA (5Y Average) | -13.52% |
| ROIC (5Y Average) | -62.46% |
| Asset Turnover | 0.28x |
Scores
VIR has an Altman Z-Score of 2.75, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.75 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $303.07M over the last 12 months.
| Revenue | $303.07M |
|---|---|
| Revenue Growth (YoY) | +1697.56% |
| Gross Profit | $303.05M |
| Operating Income | -$211.40M |
| Pretax Income | -$184.72M |
| Net Income | -$184.79M |
| Reported EPS (TTM) | -$1.26 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 80.72% of the $1.11B in total assets.
| Cash and Equivalents | $218.87M |
|---|---|
| Total Debt | $0 |
| Net Cash | $218.87M |
| Net Cash Per Share | $1.29 |
| Working Capital | $427.61M |
| Shareholder Equity | $896.04M |
| Book Value Per Share | $5.29 |
| Tangible Book Value | $871.47M |
| Tangible Book Per Share | $5.15 |
| Total Assets | $1.11B |
| Total Liabilities | $215.82M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $804.00K of capital spending, operating cash flow left -$141.82M of free cash flow.
| Operating Cash Flow | -$141.02M |
|---|---|
| Capital Expenditures | $804.00K |
| Free Cash Flow | -$141.82M |
| FCF Per Share | -$0.84 |
| Depreciation and Amortization | $14.29M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -69.75%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -69.75% |
| Pretax Margin | -60.95% |
| Net Margin | -60.97% |
| FCF Margin | -46.80% |
| Gross Margin (5Y Average) | 96.11% |
Growth
Revenue fell 65.12% a year over 3 years.
| Revenue Growth (3Y CAGR) | -65.12% |
|---|---|
| Revenue Growth (5Y CAGR) | -2.14% |
| Book Value Per Share Growth (2Y CAGR) | -31.79% |
| Tangible Book Per Share Growth (2Y CAGR) | -32.05% |
Dividends and Yields
VIR does not pay a dividend. Its free cash flow yield is -9.06%.
| FCF Yield | -9.06% |
|---|---|
| Buyback Yield | -15.35% |
| Shareholder Yield | -15.35% |
Peer Position
Against 10 similar companies, VIR has the 7th highest P/S.
P/S RatioPeer median 10.8x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +12.82%
| P/S Ratio | 5.2x vs 10.8x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +1697.56% vs +12.82% median |
Analyst Forecast
Consensus estimates put revenue growth at -1.33% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -1.33% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VIR
What is VIR's market cap?
Vir Biotechnology has a market cap of $1.64B. Its enterprise value, which adds debt and subtracts cash, is $1.42B.
How many shares of VIR are outstanding?
Vir Biotechnology has 169.28M shares outstanding. The count is up 21.84% from a year earlier.
Does VIR pay a dividend?
No. Vir Biotechnology does not pay a dividend.
How much debt does VIR have?
Vir Biotechnology has $0 of total debt and $218.87M of cash and equivalents, a net cash position of $218.87M.
VIR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts